jak3 Search Results


94
Carna Inc recombinant human jak3 catalytic domain
Recombinant Human Jak3 Catalytic Domain, supplied by Carna Inc, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/jak3/JAK3/us09284311-453-0-14
Average 94 stars, based on 1 article reviews
recombinant human jak3 catalytic domain - by Bioz Stars, 2026-11
94/100 stars
  Buy from Supplier

94
MedChemExpress jak3 inhibitor
Jak3 Inhibitor, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/jak3/JAK3+Antibody/pmc09208297-53-14-12
Average 94 stars, based on 1 article reviews
jak3 inhibitor - by Bioz Stars, 2026-11
94/100 stars
  Buy from Supplier

95
Cell Signaling Technology Inc jak3
Figure 4 Identification of NUP214-ABL1 oncogene as a new substrate of PTPN2. (a) Desphosphorylation of NUP214-ABL1 was observed upon overexpression of wild-type PTPN2 (PTPN2-WT). Immune precipitation (IP) of the catalytic mutant PTPN2-D182A resulted in coprecipitation of NUP214-ABL1. DD, destabilization domain; GFP, green fluorescent protein; WCL, whole-cell lysates. (b) Viable cell numbers determined 3 d after electroporation with small interfering RNAs (siRNAs). Decrease in PTPN2 resulted in proliferative advantage of ALL-SIL cells. (c) Cells were exposed to imatinib at time of maximal PTPN2 knockdown. Protein blot showed differential activation status of STAT family members downstream of NUP214- ABL1. ERK1/2 and an SRC-family kinase were constitutively active in ALL-SIL cells, and knockdown of PTPN2 caused an augmented phosphorylation, which stayed unchanged upon imatinib treatment. Loading control was ERK1/2. (d) IP experiments of ALL-SIL cells after electroporation with siRNAs showed an enhancing effect on <t>JAK3</t> kinase activation (upper) and identified the differentially activated SRC-family kinase as LCK. Phosphorylation of JAK3 and LCK were detected with a phosphotyrosine (pTyr) or phospho-SRC family antibody, respectively. JAK3 or LCK were used as loading controls. (e) Ba/F3 cells carrying indicated constructs were grown in the absence of IL-3, and mean growth ± s.e.m. was recorded in triplicate for 8 d. No s.e.m. is shown in case of values below 0.03. (f) Protein blot of NUP214-ABL1-dependent Ba/F3 cells demonstrated stronger constitutive activation of NUP214-ABL1 and STAT5 in case of concomitant shRNA-mediated knockdown of Ptpn2. Loading controls were c-ABL, STAT5. (g) Induced overexpression of PTPN2-WT in Ba/F3 cells carrying the NUP214-ABL fusion results in dephosphorylation of the oncogenic kinase and its downstream mediator STAT5. c-ABL is shown as loading control. Values below immunoblots represent normalized (for loading control) quantitative values. Open bars, siRNA PTPN2; closed bars, siRNA control. Bars show average ± s.e.m. Error bars represent s.e.m. *P < 0.05, **P < 0.005.
Jak3, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/jak3/Jak3+Antibody/pm20473312-340-21-29
Average 95 stars, based on 1 article reviews
jak3 - by Bioz Stars, 2026-11
95/100 stars
  Buy from Supplier

93
Selleck Chemicals jak3 pathway inhibitor jak3 inhibitor 1
Figure 4 Identification of NUP214-ABL1 oncogene as a new substrate of PTPN2. (a) Desphosphorylation of NUP214-ABL1 was observed upon overexpression of wild-type PTPN2 (PTPN2-WT). Immune precipitation (IP) of the catalytic mutant PTPN2-D182A resulted in coprecipitation of NUP214-ABL1. DD, destabilization domain; GFP, green fluorescent protein; WCL, whole-cell lysates. (b) Viable cell numbers determined 3 d after electroporation with small interfering RNAs (siRNAs). Decrease in PTPN2 resulted in proliferative advantage of ALL-SIL cells. (c) Cells were exposed to imatinib at time of maximal PTPN2 knockdown. Protein blot showed differential activation status of STAT family members downstream of NUP214- ABL1. ERK1/2 and an SRC-family kinase were constitutively active in ALL-SIL cells, and knockdown of PTPN2 caused an augmented phosphorylation, which stayed unchanged upon imatinib treatment. Loading control was ERK1/2. (d) IP experiments of ALL-SIL cells after electroporation with siRNAs showed an enhancing effect on <t>JAK3</t> kinase activation (upper) and identified the differentially activated SRC-family kinase as LCK. Phosphorylation of JAK3 and LCK were detected with a phosphotyrosine (pTyr) or phospho-SRC family antibody, respectively. JAK3 or LCK were used as loading controls. (e) Ba/F3 cells carrying indicated constructs were grown in the absence of IL-3, and mean growth ± s.e.m. was recorded in triplicate for 8 d. No s.e.m. is shown in case of values below 0.03. (f) Protein blot of NUP214-ABL1-dependent Ba/F3 cells demonstrated stronger constitutive activation of NUP214-ABL1 and STAT5 in case of concomitant shRNA-mediated knockdown of Ptpn2. Loading controls were c-ABL, STAT5. (g) Induced overexpression of PTPN2-WT in Ba/F3 cells carrying the NUP214-ABL fusion results in dephosphorylation of the oncogenic kinase and its downstream mediator STAT5. c-ABL is shown as loading control. Values below immunoblots represent normalized (for loading control) quantitative values. Open bars, siRNA PTPN2; closed bars, siRNA control. Bars show average ± s.e.m. Error bars represent s.e.m. *P < 0.05, **P < 0.005.
Jak3 Pathway Inhibitor Jak3 Inhibitor 1, supplied by Selleck Chemicals, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/jak3/Selective+JAK3+inhibitor+1/pmc10236606-30-58-64
Average 93 stars, based on 1 article reviews
jak3 pathway inhibitor jak3 inhibitor 1 - by Bioz Stars, 2026-11
93/100 stars
  Buy from Supplier

93
Santa Cruz Biotechnology anti jak3 monoclonal antibody
Figure 4 Identification of NUP214-ABL1 oncogene as a new substrate of PTPN2. (a) Desphosphorylation of NUP214-ABL1 was observed upon overexpression of wild-type PTPN2 (PTPN2-WT). Immune precipitation (IP) of the catalytic mutant PTPN2-D182A resulted in coprecipitation of NUP214-ABL1. DD, destabilization domain; GFP, green fluorescent protein; WCL, whole-cell lysates. (b) Viable cell numbers determined 3 d after electroporation with small interfering RNAs (siRNAs). Decrease in PTPN2 resulted in proliferative advantage of ALL-SIL cells. (c) Cells were exposed to imatinib at time of maximal PTPN2 knockdown. Protein blot showed differential activation status of STAT family members downstream of NUP214- ABL1. ERK1/2 and an SRC-family kinase were constitutively active in ALL-SIL cells, and knockdown of PTPN2 caused an augmented phosphorylation, which stayed unchanged upon imatinib treatment. Loading control was ERK1/2. (d) IP experiments of ALL-SIL cells after electroporation with siRNAs showed an enhancing effect on <t>JAK3</t> kinase activation (upper) and identified the differentially activated SRC-family kinase as LCK. Phosphorylation of JAK3 and LCK were detected with a phosphotyrosine (pTyr) or phospho-SRC family antibody, respectively. JAK3 or LCK were used as loading controls. (e) Ba/F3 cells carrying indicated constructs were grown in the absence of IL-3, and mean growth ± s.e.m. was recorded in triplicate for 8 d. No s.e.m. is shown in case of values below 0.03. (f) Protein blot of NUP214-ABL1-dependent Ba/F3 cells demonstrated stronger constitutive activation of NUP214-ABL1 and STAT5 in case of concomitant shRNA-mediated knockdown of Ptpn2. Loading controls were c-ABL, STAT5. (g) Induced overexpression of PTPN2-WT in Ba/F3 cells carrying the NUP214-ABL fusion results in dephosphorylation of the oncogenic kinase and its downstream mediator STAT5. c-ABL is shown as loading control. Values below immunoblots represent normalized (for loading control) quantitative values. Open bars, siRNA PTPN2; closed bars, siRNA control. Bars show average ± s.e.m. Error bars represent s.e.m. *P < 0.05, **P < 0.005.
Anti Jak3 Monoclonal Antibody, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/jak3/JAK3+Antibody/10__1074_slash_jbc__m910290199-48-5-48
Average 93 stars, based on 1 article reviews
anti jak3 monoclonal antibody - by Bioz Stars, 2026-11
93/100 stars
  Buy from Supplier

94
TargetMol endogenous metabolite compound library
Fig. 1. Normalized TMPRSS2-HiBiT signal under treatment of compounds from (A) diversified building block library, (B) bioactive compound library, or (C) human <t>endogenous</t> <t>metabolite</t> library, at concentration of 10 μM and adjusted to corresponding ATP-Glo signal.
Endogenous Metabolite Compound Library, supplied by TargetMol, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/jak3/JAK-STAT+Compound+Library/pm39156721-57-9-15
Average 94 stars, based on 1 article reviews
endogenous metabolite compound library - by Bioz Stars, 2026-11
94/100 stars
  Buy from Supplier

93
Cell Signaling Technology Inc mouse anti human jak3
Immunophenotyping of healthy control and patient P2’s peripheral blood cells by flow cytometry. A Contour flow plots showing relative abundance of B-cells and reduced T-cells, absence of CD8 + cells and naïve CD4 + cells, hyper activation of CD4 + cells, and skewing of NK-cells towards CD56-CD16 + phenotype in patient P2 with the <t>JAK3</t> R431P variant. B Quantification of flow cytometry data in controls and patient P2. Data presented as mean ± SD
Mouse Anti Human Jak3, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/jak3/Jak3+Mouse+mAb/pmc11006754-63-25-28
Average 93 stars, based on 1 article reviews
mouse anti human jak3 - by Bioz Stars, 2026-11
93/100 stars
  Buy from Supplier

90
OriGene jak3 plasmids
Immunophenotyping of healthy control and patient P2’s peripheral blood cells by flow cytometry. A Contour flow plots showing relative abundance of B-cells and reduced T-cells, absence of CD8 + cells and naïve CD4 + cells, hyper activation of CD4 + cells, and skewing of NK-cells towards CD56-CD16 + phenotype in patient P2 with the <t>JAK3</t> R431P variant. B Quantification of flow cytometry data in controls and patient P2. Data presented as mean ± SD
Jak3 Plasmids, supplied by OriGene, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/jak3/JAK3+(NM_000215)+Human+Tagged+ORF+Clone/pm34707127-281-3-8
Average 90 stars, based on 1 article reviews
jak3 plasmids - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

94
Cell Signaling Technology Inc anti p jak
Immunophenotyping of healthy control and patient P2’s peripheral blood cells by flow cytometry. A Contour flow plots showing relative abundance of B-cells and reduced T-cells, absence of CD8 + cells and naïve CD4 + cells, hyper activation of CD4 + cells, and skewing of NK-cells towards CD56-CD16 + phenotype in patient P2 with the <t>JAK3</t> R431P variant. B Quantification of flow cytometry data in controls and patient P2. Data presented as mean ± SD
Anti P Jak, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/jak3/Jak3+Rabbit+mAb/pm36889175-65-9-10
Average 94 stars, based on 1 article reviews
anti p jak - by Bioz Stars, 2026-11
94/100 stars
  Buy from Supplier

90
ABclonal Biotechnology bax
Immunophenotyping of healthy control and patient P2’s peripheral blood cells by flow cytometry. A Contour flow plots showing relative abundance of B-cells and reduced T-cells, absence of CD8 + cells and naïve CD4 + cells, hyper activation of CD4 + cells, and skewing of NK-cells towards CD56-CD16 + phenotype in patient P2 with the <t>JAK3</t> R431P variant. B Quantification of flow cytometry data in controls and patient P2. Data presented as mean ± SD
Bax, supplied by ABclonal Biotechnology, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/jak3/JAK3+Rabbit+pAb/10__1016_slash_j__cej__2022__136169-180-41-45
Average 90 stars, based on 1 article reviews
bax - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

Image Search Results


Figure 4 Identification of NUP214-ABL1 oncogene as a new substrate of PTPN2. (a) Desphosphorylation of NUP214-ABL1 was observed upon overexpression of wild-type PTPN2 (PTPN2-WT). Immune precipitation (IP) of the catalytic mutant PTPN2-D182A resulted in coprecipitation of NUP214-ABL1. DD, destabilization domain; GFP, green fluorescent protein; WCL, whole-cell lysates. (b) Viable cell numbers determined 3 d after electroporation with small interfering RNAs (siRNAs). Decrease in PTPN2 resulted in proliferative advantage of ALL-SIL cells. (c) Cells were exposed to imatinib at time of maximal PTPN2 knockdown. Protein blot showed differential activation status of STAT family members downstream of NUP214- ABL1. ERK1/2 and an SRC-family kinase were constitutively active in ALL-SIL cells, and knockdown of PTPN2 caused an augmented phosphorylation, which stayed unchanged upon imatinib treatment. Loading control was ERK1/2. (d) IP experiments of ALL-SIL cells after electroporation with siRNAs showed an enhancing effect on JAK3 kinase activation (upper) and identified the differentially activated SRC-family kinase as LCK. Phosphorylation of JAK3 and LCK were detected with a phosphotyrosine (pTyr) or phospho-SRC family antibody, respectively. JAK3 or LCK were used as loading controls. (e) Ba/F3 cells carrying indicated constructs were grown in the absence of IL-3, and mean growth ± s.e.m. was recorded in triplicate for 8 d. No s.e.m. is shown in case of values below 0.03. (f) Protein blot of NUP214-ABL1-dependent Ba/F3 cells demonstrated stronger constitutive activation of NUP214-ABL1 and STAT5 in case of concomitant shRNA-mediated knockdown of Ptpn2. Loading controls were c-ABL, STAT5. (g) Induced overexpression of PTPN2-WT in Ba/F3 cells carrying the NUP214-ABL fusion results in dephosphorylation of the oncogenic kinase and its downstream mediator STAT5. c-ABL is shown as loading control. Values below immunoblots represent normalized (for loading control) quantitative values. Open bars, siRNA PTPN2; closed bars, siRNA control. Bars show average ± s.e.m. Error bars represent s.e.m. *P < 0.05, **P < 0.005.

Journal: Nature genetics

Article Title: Deletion of the protein tyrosine phosphatase gene PTPN2 in T-cell acute lymphoblastic leukemia.

doi: 10.1038/ng.587

Figure Lengend Snippet: Figure 4 Identification of NUP214-ABL1 oncogene as a new substrate of PTPN2. (a) Desphosphorylation of NUP214-ABL1 was observed upon overexpression of wild-type PTPN2 (PTPN2-WT). Immune precipitation (IP) of the catalytic mutant PTPN2-D182A resulted in coprecipitation of NUP214-ABL1. DD, destabilization domain; GFP, green fluorescent protein; WCL, whole-cell lysates. (b) Viable cell numbers determined 3 d after electroporation with small interfering RNAs (siRNAs). Decrease in PTPN2 resulted in proliferative advantage of ALL-SIL cells. (c) Cells were exposed to imatinib at time of maximal PTPN2 knockdown. Protein blot showed differential activation status of STAT family members downstream of NUP214- ABL1. ERK1/2 and an SRC-family kinase were constitutively active in ALL-SIL cells, and knockdown of PTPN2 caused an augmented phosphorylation, which stayed unchanged upon imatinib treatment. Loading control was ERK1/2. (d) IP experiments of ALL-SIL cells after electroporation with siRNAs showed an enhancing effect on JAK3 kinase activation (upper) and identified the differentially activated SRC-family kinase as LCK. Phosphorylation of JAK3 and LCK were detected with a phosphotyrosine (pTyr) or phospho-SRC family antibody, respectively. JAK3 or LCK were used as loading controls. (e) Ba/F3 cells carrying indicated constructs were grown in the absence of IL-3, and mean growth ± s.e.m. was recorded in triplicate for 8 d. No s.e.m. is shown in case of values below 0.03. (f) Protein blot of NUP214-ABL1-dependent Ba/F3 cells demonstrated stronger constitutive activation of NUP214-ABL1 and STAT5 in case of concomitant shRNA-mediated knockdown of Ptpn2. Loading controls were c-ABL, STAT5. (g) Induced overexpression of PTPN2-WT in Ba/F3 cells carrying the NUP214-ABL fusion results in dephosphorylation of the oncogenic kinase and its downstream mediator STAT5. c-ABL is shown as loading control. Values below immunoblots represent normalized (for loading control) quantitative values. Open bars, siRNA PTPN2; closed bars, siRNA control. Bars show average ± s.e.m. Error bars represent s.e.m. *P < 0.05, **P < 0.005.

Article Snippet: We used the antibodies to the following: c-ABL (24-11), ERK (C-16), LCK (3A5), LCK (2102), phospho-JAK1 (Tyr1022/1023) (Santa Cruz); JAK2 (D2E12), JAK3, phospho-SRC (Tyr416), phospho-AKT (Ser473), phospho-ERK1/2 (9101), c-ABL (Cell Signaling); phosphotyrosine (4G10), JAK1 (Upstate); PTPN2 (clone CF4-1D, Calbiochem); Ptpn2 (3E2, MÉDIMABS); phospho-ABL (Tyr245, Sigma).

Techniques: Over Expression, Mutagenesis, Electroporation, Knockdown, Activation Assay, Phospho-proteomics, Control, Construct, shRNA, De-Phosphorylation Assay, Western Blot

Fig. 1. Normalized TMPRSS2-HiBiT signal under treatment of compounds from (A) diversified building block library, (B) bioactive compound library, or (C) human endogenous metabolite library, at concentration of 10 μM and adjusted to corresponding ATP-Glo signal.

Journal: Biochemistry and biophysics reports

Article Title: NanoLuciferase technology-based detection of TMPRSS2 as attempt to develop anti-coronavirus agents.

doi: 10.1016/j.bbrep.2024.101783

Figure Lengend Snippet: Fig. 1. Normalized TMPRSS2-HiBiT signal under treatment of compounds from (A) diversified building block library, (B) bioactive compound library, or (C) human endogenous metabolite library, at concentration of 10 μM and adjusted to corresponding ATP-Glo signal.

Article Snippet: Diversified building block compound library, bioactive compound library and endogenous metabolite compound library were from TargetMol.

Techniques: Blocking Assay, Drug discovery, Concentration Assay

Immunophenotyping of healthy control and patient P2’s peripheral blood cells by flow cytometry. A Contour flow plots showing relative abundance of B-cells and reduced T-cells, absence of CD8 + cells and naïve CD4 + cells, hyper activation of CD4 + cells, and skewing of NK-cells towards CD56-CD16 + phenotype in patient P2 with the JAK3 R431P variant. B Quantification of flow cytometry data in controls and patient P2. Data presented as mean ± SD

Journal: Journal of Clinical Immunology

Article Title: Omenn Syndrome in Two Infants with Different Hypomorphic Variants in Janus Kinase 3

doi: 10.1007/s10875-024-01699-5

Figure Lengend Snippet: Immunophenotyping of healthy control and patient P2’s peripheral blood cells by flow cytometry. A Contour flow plots showing relative abundance of B-cells and reduced T-cells, absence of CD8 + cells and naïve CD4 + cells, hyper activation of CD4 + cells, and skewing of NK-cells towards CD56-CD16 + phenotype in patient P2 with the JAK3 R431P variant. B Quantification of flow cytometry data in controls and patient P2. Data presented as mean ± SD

Article Snippet: Membranes were blocked for 60 min in 5% bovine serum albumin in tris-buffered saline with 0.1% Tween (TBS-T) buffer before overnight immunostaining at 4°C with mouse anti-human JAK3 (Cell Signaling, 5481S, 1:1000) and rabbit anti-human GAPDH antibodies (Cell Signaling, 8884S, 1:5000).

Techniques: Control, Flow Cytometry, Activation Assay, Variant Assay

Impaired pSTAT5 response to interleukin IL-2, IL-7, and IL-15 stimulation in patient P2’s PBMC subsets . A Unaffected expression of JAK3 R431P protein in EBV-LCL cell lines by immunoblotting. B Histograms of pSTAT5 in patient P2’s and healthy controls’ (C1, C2) peripheral CD4 cells in response to IL-2, IL-7, and IL-15 stimulation. Dashed area: IL-stimulation, empty line: unstimulated. C Impaired pSTAT5 response to interleukin IL-2, IL-7, and IL-15 stimulation in patient P2’s cell subsets. C: Controls C1 and C2, P: patient P2, pSTAT5: phosphorylated STAT5. Data presented as mean ± SD

Journal: Journal of Clinical Immunology

Article Title: Omenn Syndrome in Two Infants with Different Hypomorphic Variants in Janus Kinase 3

doi: 10.1007/s10875-024-01699-5

Figure Lengend Snippet: Impaired pSTAT5 response to interleukin IL-2, IL-7, and IL-15 stimulation in patient P2’s PBMC subsets . A Unaffected expression of JAK3 R431P protein in EBV-LCL cell lines by immunoblotting. B Histograms of pSTAT5 in patient P2’s and healthy controls’ (C1, C2) peripheral CD4 cells in response to IL-2, IL-7, and IL-15 stimulation. Dashed area: IL-stimulation, empty line: unstimulated. C Impaired pSTAT5 response to interleukin IL-2, IL-7, and IL-15 stimulation in patient P2’s cell subsets. C: Controls C1 and C2, P: patient P2, pSTAT5: phosphorylated STAT5. Data presented as mean ± SD

Article Snippet: Membranes were blocked for 60 min in 5% bovine serum albumin in tris-buffered saline with 0.1% Tween (TBS-T) buffer before overnight immunostaining at 4°C with mouse anti-human JAK3 (Cell Signaling, 5481S, 1:1000) and rabbit anti-human GAPDH antibodies (Cell Signaling, 8884S, 1:5000).

Techniques: Expressing, Western Blot